Brought to you by 
Accentia Biopharmaceuticals brings in $8.7mm privately
10 Mar 2008
Executive Summary
Accentia Biopharmaceuticals (develops already-approved drugs for additional conditions) has raised $8.7mm by selling new and existing institutional investors preferred stock that converts into common shares at $2.67 apiece. The buyers also received short-term warrants (exercisable either 30 days after the company unveils the results of a Phase III rhinosinusitis study of SinuNase or during the 30 days after December 2, 2008) and six-year warrants to buy shares at $2.67 each. Rodman & Renshaw was the exclusive placement agent.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Accentia Biopharmaceuticals brings in $8.7mm privately
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice